FIELD: organic chemistry.
SUBSTANCE: invention relates to a heterocyclic compound of formula (I) or a pharmaceutically acceptable salt thereof, where R1 represents CO2R2; R2 is H, (C1-C6)-alkyl or (C1-C6)-aminoalkyl; X1 and X2 are H; Y is C=O; Z represents or; A1 is S; A2 is N; A3 is O; and R3-R6 are independently hydrogen, halogen or haloalkyl. The invention also relates to specific compounds and a pharmaceutical composition based on a compound of formula (I) or a specific compound.
EFFECT: effective inhibition of aldoreductase activity in the treatment of such diseases as diabetes, neuropathy, retinopathy, nephropathy and cardiomyopathy.
38 cl, 1 tbl, 17 ex
Title | Year | Author | Number |
---|---|---|---|
CFTR REGULATORS AND THEIR APPLICATION METHODS | 2016 |
|
RU2749834C2 |
CFTR REGULATORS AND METHODS OF USING | 2016 |
|
RU2730855C2 |
OPHTHALMIC PHARMACEUTICAL COMPOSITIONS | 2018 |
|
RU2818087C2 |
ANDROGEN RECEPTOR MODULATORS AND METHODS FOR THEIR USE | 2019 |
|
RU2797622C2 |
CFTR REGULATORS AND METHODS FOR USE THEREOF | 2016 |
|
RU2742934C2 |
ENPP1 INHIBITORS AND METHODS OF MODULATING THE IMMUNE RESPONSE | 2018 |
|
RU2800798C2 |
BENZOTHIOPHENE SELECTIVE ESTROGEN RECEPTOR BLOCKERS | 2016 |
|
RU2747802C2 |
MDM2 PROTEIN DESTRUCTORS | 2017 |
|
RU2743432C2 |
SUBSTITUTED PYRAZOLOPYRIMIDINES AS GLUCOCEREBROSIDASE ACTIVATORS | 2011 |
|
RU2603637C2 |
AMPK LOW-MOLECULAR ACTIVATORS | 2017 |
|
RU2766146C2 |
Authors
Dates
2023-05-02—Published
2017-06-21—Filed